Topics

Acer's shares drop 80% as FDA rejects drug for vascular Ehlers-Danlos syndrome

06:41 EDT 26 Jun 2019 | Pharmafile

Acer Therapeutics has seen its share value plunge by 80% after it emerged that the FDA had turned down its drug application for Edsivo (celiprolol) in the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.

In the complete response letter sent to the firm by the US regulator, concerns were raised over the integrity of the clinical trial data submitted in support of the application.

read more

Original Article: Acer's shares drop 80% as FDA rejects drug for vascular Ehlers-Danlos syndrome

NEXT ARTICLE

More From BioPortfolio on "Acer's shares drop 80% as FDA rejects drug for vascular Ehlers-Danlos syndrome"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Vascular
Vascular relates to blood vessels (Oxford Medical Dictionary) and can be used to describe the supply of blood, a disease affecting the blood vessels or molecules associated with these structures. For example, <!--LGfEGNT2Lhm-->atherosclerosis ...